About Us
About Us - The Advisory Team
photo of Karl Bozicevic

Karl Bozicevic, Patent Attorney

Partner in Bozicevic, Filed & Francis a leading intellectual property firm focused on the life science industry.

David Feigal, M.D., M.P.H.

Dr Feigal has held senior positions in all three FDA medical product Centers including service as former Center Director, CDRH, former Deputy Center Director, CBER and former Director of the Office of Drug Evaluation IV (Anti-infective-Antiviral Drug Products), CDER. He has a detailed understanding of the relationship between scientific evidence and regulatory strategy in product development. Before joining FDA, Dr. Feigal was an Associate Professor at the University of California, San Diego, in the Department of Medicine and is trained as a Clinical Epidemiologist. He holds an M.D. degree from Stanford University and an M.P.H. from the University of California Berkeley.

Alan Mendelson, General Counsel

Partner at Latham & Watkins and serves as the Co-Chair of the firm’s Venture and
Technology Group.

Tunde Otulana

Dr. Otulana, a practicing pulmonologist, was the Senior Vice President, Development and Chief Medical Officer at Aradigm until December 2008. From 1991 to 1997, Dr. Otulana was a medical officer and clinical team leader in Pulmonary Drug Products at the Center for Drug Evaluation and Research of the FDA. He was responsible for or participated in the FDA review and approval of major asthma drugs currently marketed in the US as well as major FDA initiatives in the pulmonary drug area. He obtained his M.D. degree at University of Ibadan, Nigeria and completed training in Internal Medicine at the University College Hospital, Ibadan, and in pulmonary medicine at Papworth Hospital, Cambridge, England and Howard University Hospital, Washington, DC. Dr. Otulana served on the FDA's Anesthesiology and Respiratory Therapy Devices Advisory Committee for four years ending November 2005. He serves on the Editorial Board of the Journal of Aerosol Medicine and he is an Editorial Reviewer for Chest. He is a member of United Nations Environmental Program (UNEP) Aerosol Technical Options Committee charged with overseeing the phase-out of CFCs under the Montreal Protocol. Dr. Otulana is an Associate Clinical Professor in Pulmonary and Critical Care Medicine, University of California, Davis, where he teaches and also runs an outpatient chest clinic. He is an author on many original scientific publications and is currently Senior Vice President, Chief Medical Officer at Aerovance which is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic inflammatory diseases.

Copyright © 2001 - 2016 Flow Pharma Inc., All rights reserved